Complementing these mechanisms, in KRAS-driven malignancies, suppression of the type I interferon (IFN) pathway emerges as a critical mechanism of tumor immune evasion, with pathway inactivation demonstrating strong correlation with concurrent activation of oncogenic signaling networks such as MYC (121). Here, MYC is linked to neoplasm.